Search
Now showing items 11-20 of 30
Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer
(1999)
Sixty patients with poor prognostic features, either with extensive disease (ED) or limited disease (LD) small cell lung cancer (SCLC), were treated on an out-patient basis with Carboplatin 80 mg/m2 weekly for 3 weeks and ...
Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: A hellenic cooperative oncology group study
(1998)
Purpose. To evaluate the outcome and the prognosis of patients with ovarian germ cell malignancies who were treated with platinum-based chemotherapy immediately after initial surgery. Methods. We conducted a retrospective ...
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group
(2005)
Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for ...
Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEPO): A prospective, open label, randomized trial by the hellenic cooperative oncology group
(2003)
Objectives: Platinum compounds are commonly associated with significant anemia. Erythropoietin administration has been found effective in correcting anemia in patients with solid tumors receiving chemotherapy. We conducted ...
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
(2014)
Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A hellenic cooperative oncology group (HECOG) study
(2012)
Background: The ubiquitin-proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression. In the present study, we sought to explore the ...
A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin
(2007)
Objective: The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast ...
Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: A study of the Hellenic Cooperative Oncology Group
(1999)
This trial was conducted by the Hellenic Cooperative Oncology Group to improve the responses and survival in small cell lung cancer with a good prognosis, using a weekly intensive chemotherapy with alternated non-cross- ...
Epithelial ovarian cancer in Greece: A retrospective study of 1,791 patients by the hellenic cooperative oncology group (HeCOG)
(2009)
Background: The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC). Patients and Methods: ...
Diffuse large cell lymphomas: Identification of prognostic factors and validation of the international non-Hodgkin's Lymphoma Prognostic Index
(1998)
Several clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently ...